Online ISSN 2313-1519
Print    ISSN 1812-2892
Abstract - Vaccination status (PCV13) of children with pneumococcal meningitis
Aliya Seidullayeva, Dinagul Bayesheva, Bayan Turdalina, Alyona Altynbekova, Aliya Omarova, Meruert Khamitova, Sabit Tashenov, Aislu Otarbayeva, Samat Kozhakhmetov


Pneumococcal meningitis in children is one of the reasons for the development of serious neurological complications. According to various authors, in developed countries, the incidence rate ranges from 8 to 34 cases per 100,000 population, in Kazakhstan there is no etiological interpretation of bacterial meningitis, and therefore there are no official statistics on the incidence. To date, in more than 120 countries, the pneumococcal conjugate vaccine has been added to the vaccination calendar, which is the most effective method for reducing the incidence of bacterial meningitis pneumococcal etiology. This article reflects the effectiveness of vaccination and the risk of bacterial meningitis in children with pneumococcal meningitis in terms of using the PCV13 vaccine.

Keywords: pneumococcal meningitis, vaccination, PVC13, children

Corresponding Author: Aliya Seidullayeva, PhD, teaching assistant, Department of Pediatric Infectious Diseases, Astana Medical University. Address: 51a, Beibitshilik Street, Nur-Sultan city, Republic of Kazakhstan. Tel.: 8 701 186 0303. E-mail:   




1. Isaacman D.J., McIntosh Ed Fau-Reinert R.R., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010; 14:197-209.

2. Juergens C., Trammel J., Shoji Y. et al. Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations. Hum Vaccin Immunother. 2018; 14(8):1948-1956.

3. Li Y.A., Tsang R., Desai S., Deehan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. Canada communicable disease report. 2014; 40(9):160-169.

4. Van Opijnen T., Lazinski D.W., Camilli A. Genome-Wide Fitness and Genetic Interactions Determined by Tn-seq, a High-Throughput Massively Parallel Sequencing Method for Microorganisms. Curr Protoc Mol Biol. 2014; 16:1-24.

5. van de Vooren K., Duranti S., Curto A., Garattini L. Cost Effectiveness of the New Pneumococcal Vaccines: A Systematic Review of European Studies. Pharmaco Economics. 2014; 32:29-45.

6. Balsells E., Guillot L., Nair H., Kyaw M.H. Kyaw Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One. 2017; 12(5):1-20.

7. Duan K., Guo J., Lei P. Safety and Immunogenicity of Pneumococcal Conjugate Vaccine in Preterm Infants: A Meta-Analysis. Indian J Pediatr. 2017; 84:101-110.

8. Chen S., Zhou Y., Chen Y., Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018; 34(17):i884-i890.

9. Szynczewska E., Chlebna-Sokół D. Immunogenicity of heptavalent conjugate vaccine against Streptococcus Pneumoniae in premature babies with low birth weight. PediatrNeonatol. 2014; 55:101-117.

Volume 2, Number 56 (2020)